
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Givinostat HCl
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Recipient : Italfarmaco S.p.A
Deal Size : Undisclosed
Deal Type : Agreement
Italfarmaco Announces Exclusive Distribution Agreement with Multicare Pharma in Brazil
Details : Multicare Pharma will support the regulatory approval in Brazil and distribute Duvyzat (givinostat), Italfarmaco’s novel histone deacetylase (HDAC) inhibitor to treat Duchenne muscular dystrophy.
Product Name : Duvyzat
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 16, 2025
Lead Product(s) : Givinostat HCl
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Recipient : Italfarmaco S.p.A
Deal Size : Undisclosed
Deal Type : Agreement
